Not medical advice. A record of published research and our assessments of it. The limits

The cardiovascular benefit of GLP-1 receptor agonists is not explained by weight loss.

Current status: ProbableEvidence strengthening · Cardiovascular
Why: In SELECT (obesity + CVD, no diabetes) MACE reduction was consistent across baseline weight categories and showed no linear relationship with early weight loss; an estimated 33% of benefit was mediated via waist reduction. Class-wide CVOTs in type 2 diabetes show similar relative reductions with modest weight loss. This supports mechanisms beyond adiposity in people who already have obesity and atherosclerotic disease; it does not show benefit in people without excess adiposity.
What would change it: A primary-prevention outcome trial in people without obesity (would strengthen).

A weight-matched comparison showing loss of CV benefit when weight loss is equalised (would weaken).
Linked studies: 6 · 4 supports · 2 mixed
Last updated: Sep 13, 2026

The status is the collection's own judgment on its assessment scale, not a GRADE certainty rating and not medical advice.

01The evidence

The evidence, sorted by what it shows

Effect of Semaglutide on the Inflammatory Biomarker High-Sensitivity CRP in Patients With Established Cardiovascular Disease and Overweight or Obesity in SELECT: A Prespecified Secondary AnalysisPrespecified secondary (sub-study) analysis of a randomized, double-blind, placebo-controlled, parallel-group phase 3 trial (select) · 2026 · Study tier 2 · Different population · Benefit · Industry funded
hs-CRP reduction prognostic of MACE reduction; modelling attributes part of benefit to inflammation.
Semaglutide and cardiovascular outcomes by baseline and changes in adiposity measurements: a prespecified analysis of the SELECT trialRandomized trial · 2025 · Study tier 2 · Different population · Benefit · Industry funded
Prespecified SELECT analysis: benefit independent of baseline adiposity and early weight loss; ~33% mediated by waist circumference change.
Semaglutide and Cardiovascular Outcomes in Obesity without DiabetesRandomized trial · 2023 · Study tier 1 · Different population · Benefit · Industry funded
SELECT primary result: HR 0.80 for MACE in obesity without diabetes.
Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trialsMeta-analysis · 2021 · Study tier 1 · Different population · Benefit
Meta-analysis of 8 CVOTs in T2D: MACE HR 0.86 with modest weight loss.

Cardiovascular Outcomes of GLP-1-Based Medicines Among People With Overweight and Obesity: An Umbrella Review of Meta-Analyses of Randomized Controlled TrialsUmbrella review · 2026 · Study tier 2 · Different population · Mixed
Umbrella review: benefit confined to those with established CVD; no signal in primary prevention.
Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 DiabetesRandomized trial · 2025 · Study tier 1 · Different population · Mixed · Industry funded
SURPASS-CVOT: tirzepatide (much greater weight loss) was noninferior but not superior to dulaglutide for MACE, arguing against a simple weight-loss dose-response for CV events.

02History